The PRMT5 inhibitor GSK3326595 has been shown to promote the alternative splicing of the human ortholog of mouse double minute 4 (MDM4), which leads to the activation of the tumour suppressor p53 protein and reduced tumour cell viability (Gerhart et al. 2018). The gene discussed is PRMT5; the disease is neoplasm.